Vigabatrin Tablet
Product Images NDC 59651-367

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Vigabatrin (NDC 59651-367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Vigabatrin Fig1)

The text is a description of a figure showing the percent reduction from baseline in seizure frequency. The figure includes a scale from 0 to 50 on the y-axis showing the percentage of patients, and four treatment groups on the x-axis: placebo, 1g/day vigabatrin, 30/day vigabatrin, and 6g/day vigabatrin. For each group, there are three bars representing the percentage of patients who experienced improvement, no change, or worsening of their seizures.*

FDA Label Image

Figure 2 (Vigabatrin Fig2)

The text is describing a graph showing the percent reduction from baseline in seizure frequency for patients taking either a placebo or 3g/day of vigabatrin. The X-axis shows the percentage of patients, while the Y-axis shows the percent reduction in seizure frequency. The graph demonstrates a significant improvement in seizure frequency for patients taking 3g/day vigabatrin, with a decrease in seizure frequency of 50% or more for 100% of patients, whereas the placebo group showed no improvement.*

FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Carton Label))

FDA Label Image

Str (Vigabatrin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.